# Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia

> **NCT05804734** · — · COMPLETED · sponsor: **Groupe Maladies hémorragiques de Bretagne** · enrollment: 54 (actual)

## Conditions studied

- Hemophilia A
- Hemophilia B
- Anticoagulant-induced Bleeding

## Interventions

- **DRUG:** Vitamin K Antagonist - Drug

## Key facts

- **NCT ID:** NCT05804734
- **Lead sponsor:** Groupe Maladies hémorragiques de Bretagne
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05804734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05804734, "Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05804734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*